CARB-X
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership that supports the best science from around the world of new antibiotics, vaccines, rapid diagnostics and other products to prevent and treat high priority drug-resistant bacteria considered the world’s biggest health threats by the Centers for Disease Control and Prevention and the World Health Organization[1]
CARB-X was launched in the summer of 2016 at the Boston University School of Law, where CARB-X Executive Director Professor Kevin Outterson teaches health law, corporate law, and co-directs the Health Law Program.[2] In its first five years, CARB-X awarded $361 million to 92 projects across the globe.[3]
CARB-X focuses on the early stages of research and development when projects are most vulnerable. For diagnostics, CARB-X supports the process from feasibility into product verification and validation. For therapeutics and preventatives, CARB-X supports lead discovery through preclinical development, and into a demonstration of safety in human clinical studies. CARB-X aims for projects to be well positioned to attract additional support for further clinical development and approval for use in patients.[4]
CARB-X is funded by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR); the Wellcome Trust, a UK-based global charitable foundation supporting science to solve the urgent health challenges facing everyone; Germany’s Federal Ministry of Education and Research (BMBF); the UK Government’s Global Antimicrobial Resistance Innovation Fund (UK GAMRIF); and the Bill & Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world. CARB-X also receives in-kind support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).[5]
References[]
- ^ "CARB-X Global Partnership | School of Law". www.bu.edu. Retrieved 2021-12-21.
- ^ "CARB-X Global Partnership". Boston University. Retrieved 2021-06-18.
- ^ "CARB-X 2020-2021 Annual Report" (PDF). CARB-X.
- ^ "CARB-X Global Partnership | School of Law". www.bu.edu. Retrieved 2021-12-21.
- ^ "CARB-X Global Partnership | School of Law". www.bu.edu. Retrieved 2021-12-21.
External links[]
- Non-profit corporations
- Partnerships
- Boston University School of Law
- Antimicrobial resistance organizations
- Funding bodies
- Non-profit organization stubs